M-1121 (100 mg/kg; p.o.; 26 days) reduces the average tumor volume from 157 mm3 at the beginning of the treatment to 106 mm3 on day 26 of the treatment, a reduction of tumor volume of 32%[1].
M-1121 (300 mg/kg; p.o.) leads to complete tumor regression in 10 out of 10 mice with no tumor regrowth detected up to a month after last treatment[1].
M-1121 (5 mg/kg; p.o.) has a low clearance and a moderate volume of distribution[1].
| Animal Model: | SCID mice[1] |
| Dosage: | 100 mg/kg |
| Administration: | P.o. |
| Result: | Reduced the average tumor volume from 157 mm3 at the beginning of the treatment to 106 mm3 on day 26 of the treatment, a reduction of tumor volume of 32%.
|
| Animal Model: | SCID mice[1] |
| Dosage: | 300 mg/kg |
| Administration: | P.o. |
| Result: | Led to complete tumor regression in 10 out of 10 mice with no tumor regrowth detected up to a month after last treatment.
|
| Animal Model: | Female C57BL/6 mice[1] |
| Dosage: | 5 mg/kg (Pharmacokinetic Analysis) |
| Administration: | P.o. |
| Result: | Had a low clearance and a moderate volume of distribution.
|
![Carbamic acid, N-[(1S,2R)-2-[(1S)-2-(1-azetidinyl)-1-(3-fluorophenyl)-1-[1-[[3-methoxy-1-[4-[[(1S,4S)-5-(1-oxo-2-propen-1-yl)-2,5-diazabicyclo[2.2.1]hept-2-yl]sulfonyl]phenyl]-3-azetidinyl]methyl]-4-piperidinyl]ethyl]cyclopentyl]-, methyl ester Structure](https://www.chemicalbook.com/CAS/20211123/GIF/2377337-93-2.gif)